Posted on

Proviron 25mg

proviron 25mg

Before treatment of patients drug proviron 25mg to exclude malignancy of the prostate or other reasons leading to urinary retention. The efficacy of the therapy was assessed after 4-6 weeks of treatment with maintenance doses of the drug terazosin -Teva. Reducing the symptoms of BPH may already be on the second week of therapy, however, the onset of therapeutic effect may be delayed up to Use of proviron 25mg6 weeks or more. After application of the maximum recommended dose should be discontinued if the uroflowmetry improvement in performance is slightly different from the baseline. Drug treatment should be stopped if there are side effects are more serious than the symptoms of or the development of patient complications from urinary tract while taking the drug.Regardless of the proviron for sale indications for which , in order to avoid the development of “first-dose effect” initial dose of terazosin -Teva should not exceed 1 mg.

To reduce the risk of orthostatic hypotension ( “effect of the first dose”), the first drug dose recommended to take in the evening before going to sleep, then the patient should be in bed for 6-8 hours. The risk of significant decrease in blood pressure is highest within 30-90 minutes after taking the drug, as well as increased in patients concomitantly receiving beta-blockers and diuretics, with a decrease in circulating blood volume, malosolevoy diet, as well as the resumption of treatment with after a break (a few days).

The patient should be informed that at the first signs of orthostatic hypotension (dizziness, weakness), the patient should sit or lie down and remain in that position for as long as the state of health did not improve, as well as to increase the risk of pronounced reduction in blood pressure when consuming alcohol, prolonged standing or performing physical exercise and at high ambient temperatures.

use caution while use of the drug terazosin -Teva with thiazide diuretics or other antihypertensive agents; if necessary dose combination therapy reduces -Teva terazosin. Concomitant use of proviron 25mg inhibitors, including sildenafil, tadalafil, vardenafil and terazosin -Teva drug may lead to a marked reduction in blood pressure in some patients. In order to minimize the risk of orthostatic hypotension, before the use is necessary to ensure that the blood pressure of the patient was stable against the background of treatment .

Selection of a maintenance dose of the drug proviron 25mg in elderly patients, especially in patients with BPH patients aged over 65 years, is recommended with caution under medical supervision, because of the high risk of orthostatic hypotension in this patient group.

in connection with the manifestation of the vasodilator effect of the drug -Teva terazosin should be used with caution in patients with coronary artery disease or other heart disease: swelling light with aortic or mitral stenosis, heart failure with an increase in minute ejection, right ventricular failure caused by pulmonary embolism or exudative pericarditis, left ventricular failure with low pressure ventricular filling.

In some patients previously treated with tamsulosin, during surgery for cataracts was noted “flabby intraoperative iris syndrome” (ISDR, kind of narrow pupil syndrome). Some reports have also been received and the application of other blockers of alpha1-adrenergic receptors, so we can not exclude the possible influence of the class of these drugs.

Proviron 25mg

During the surgery (cataract) must inform the surgeon-ophthalmologist on the use of blockers of alpha1 – adrenergic receptors.

When applied in a violation of patients liver caution due to the fact that terazosin metabolism in the liver. Data on the use of the drug terazosin -Teva in patients with severe hepatic impairment are not available.

In the course of treatment does not change the concentration of proviron 25mg.

Effects on ability to drive vehicles and other mechanisms within 12 hours after the first dose, after an increase in dose or interrupt treatment to patients is not recommended to engage in potentially hazardous activities that require increased attention and quickness of psychomotor reactions (including driving vehicles). Further limitations degree should be set depending on the individual patient response.